WuXi AppTec, via its laboratory testing division, has opened a new medical device testing center in Suzhou, China.
The new center will allow WuXi AppTec to fully implement its medical device testing capabilities in the Chinese market.
WuXi AppTec’s new center will also coordinate with its existing US-based medical device testing centers in St. Paul and Atlanta to establish a globally integrated medical device testing platform to provide services to the medical device customers across the globe.
The firm’s laboratory testing division allows medical device firms to effectively control product quality in its product life cycle from R&D to commercial sales through offering integrated medical device testing and regulatory services ranging from research and development to commercialization.
The new 15,000m² facility has adopted the capabilities, operation and quality management system from the firm’s US medical device testing center.
Suzhou medical device testing center will offer comprehensive medical device testing services, which are in compliance with international quality standards.
The testing services offered include biomaterials analysis, toxicology, biocompatibility, risk assessment, product aseptic design microbiology, physical testing of packaging and shelf life, product batch release testing and others.
WuXi AppTec’s new facility will allow medical device companies to provide major medical and health products to patients in China and across the globe.
WuXi AppTec senior vice president and WuXi AppTec’s laboratory testing division chief operating officer Dr Jason Liu said: “WuXi AppTec’s Laboratory Testing Division provides a world-class, globally integrated testing solution for drug and medical device development and manufacturing.
“We enable scientists to transform ideas into healthcare products, accelerate the development and commercialization from bench to bedside.”
WuXi AppTec is a global pharmaceutical and medical device open-access capability and technology platform firm, which offers a wide and integrated portfolio of services to its customers across the world.
The company’s capabilities comprise of small molecule drug R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, drug R&D and medical device testing.
Its platform is supporting more than 3,000 collaborators from over 30 countries to bring advanced healthcare products for the treatment of patients.